Kaitlyn D’Onofrio

DocwireNews

Glucocorticoids have been used in <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/tofacitinib-baricitinib-upadacitinib-filgotinib-or-peficitinib-study-compares-five-rheumatoid-arthritis-monotherapies/">rheumatoid arthritis</a> (RA) for decades and in recent years have been used as disease-modifying therapy. And although the risk/benefit ratio of glucocorticoids has been questioned, data have shown that low-dose glucocorticoids in conjunction with disease-modifying antirheumatic drugs (DMARDs) have been beneficial for RA patients. A study compared the effect of low-dose glucocorticoids plus methotrexate and hydroxychloroquine versus placebo plus methotrexate and <a href="https://www.docwirenews.com/docwire-pick/cardiology-picks/hydroxychloroquine-associated-with-increased-mortality-risk-covid-19/">hydroxychloroquine</a> on symptoms, signs, and inflammation in early RA.The study randomized 80 untreated early RA patients to either the trial group (glucocorticoids plus DMARDs) or control group (placebo plus DMARDs) for one year of treatment. Outcomes included the American College of Rheumatology 20 (ACR20) criteria, disease activity score (DAS) 28- erythrocyte sedimentation rate (ESR), visual analog scale scores, joint function, health assessment questionnaire-disability index score, morning stiffness duration, C-reaction protein, and ESR. Clinical outcomes were assessed at baseline and months one, three, six and 12. A revised OMERACT RAMRIS Scoring System was used to collect MRI data of each patient&rsquo;s most swollen joint pre- and posttreatment. Patients were also monitored for side effects including gastrointestinal reactions, liver dysfunction, upper respiratory tract infection, and leukocyte reduction.After one month of treatment, ACR20 response was achieved by 55% of the glucocorticoids group and 20% of the placebo group. At month three, 85.0% of the glucocorticoids group and 47.5% of the placebo group achieved ACR20 response; at months six and 12, the rates were 87.5% versus 60.0%, respectively, and 90.0% versus 72.5%, respectively (P&lt;0.05 for all). During the first half of the treatment period, the trial group had significantly lower DAS28-ESR scores than the control group. Inflammation, quality of life, and radiological symptoms improved significantly in the glucocorticoids group. Bone erosion did not change in the trial group and worsened in the control group. The correlation coefficient between disease duration and DAS28-ESR score was 0.496 for month one, 0.464 for month three, 0.509 for month six, and 0.550 for month 12. Rates of adverse events (AEs) did not largely differ between the groups.Reporting in <a href="https://journals.lww.com/md-journal/FullText/2020/07020/Efficacy_and_safety_of_low_dose_glucocorticoids.47.aspx">Medicine</a>, the researchers concluded that low-dose glucocorticoids plus DMARDs methotrexate and hydroxychloroquine provided &ldquo;excellent results&rdquo; in patients with early RA, leading to significant improvements in symptoms, signs, and inflammation compared to placebo plus DMARDs without increasing the risk for AEs.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Low-dose Glucocorticoids Plus Methotrexate and Hydroxychloroquine Effective in Early RA

Rheumatoid Arthritis

Glucocorticoids have been used in rheumatoid arthritis (RA) for decades and in recent years have been used as disease-modifying therapy. And although the risk/benefit ratio of ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe